Navigation Links
Arena Pharmaceuticals Provides Update on GPR119 Portfolio for Type 2 Diabetes
Date:11/4/2010

abolic diseases. Arena's most advanced drug candidate, lorcaserin, is intended for weight management. Arena's wholly owned subsidiary, Arena Pharmaceuticals GmbH, has granted Eisai Inc. exclusive rights to market and distribute lorcaserin in the United States, subject to FDA approval of the New Drug Application for lorcaserin.

Arena Pharmaceuticals(R) and Arena(R) are registered service marks of the company.

Forward-Looking StatementsCertain statements in this press release are forward-looking statements that involve a number of risks and uncertainties. Such forward-looking statements include statements about the termination of Arena's collaboration with Ortho-McNeil-Janssen and related expectations and future activities; the therapeutic indication and use, safety, efficacy, tolerability, mechanism of action and potential of APD597 alone and in combination; the potential of GPR119; Arena's GPR119 patent portfolio and program and potential opportunities; the potential therapeutic indication and use, FDA approval and commercialization of lorcaserin; and Arena's focus, goals, strategy, research and development programs, and ability to develop compounds and commercialize drugs. For such statements, Arena claims the protection of the Private Securities Litigation Reform Act of 1995. Actual events or results may differ materially from Arena's expectations. Factors that could cause actual results to differ materially from the forward-looking statements include, but are not limited to, the risk that APD597 or GPR119 agonists as a class may not realize their potential or ever receive marketing approval; the risk that regulatory authorities may not find data and other information related to Arena's clinical trials and other studies sufficient for regulatory approval; the timing of regulatory review and approval is uncertain; Arena's response to the complete response letter for the lorcaserin NDA may not be submitted in a timely manner and/or the information
'/>"/>

SOURCE Arena Pharmaceuticals, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related medicine technology :

1. Endologix Announces Publication of Clinical Trial Results Supporting Anatomical Fixation with a Suprarenal Aortic Extension
2. Arena and Eisai Announce Upcoming Lorcaserin Presentations at Obesity 2010
3. Arena and Eisai Provide Update on Lorcaserin FDA Advisory Committee Meeting
4. Arena Pharmaceuticals to Host Conference Call and Webcast Following Lorcaserin FDA Advisory Committee Meeting
5. Arena Pharmaceuticals Submits New Drug Application to FDA for Lorcaserin for Weight Management
6. Published Data Demonstrate Arena Pharmaceuticals Lorcaserin Has Low Abuse Potential
7. Arena Pharmaceuticals Announces Third Quarter 2009 Financial Results and Recent Developments
8. Arena Pharmaceuticals to Host Business and Financial Update Conference Call and Webcast on Tuesday, November 10, 2009
9. Arena Pharmaceuticals Lorcaserin to be Featured in Multiple Presentations at Obesity 2009
10. Arena Pharmaceuticals Reports Positive, Highly Significant BLOSSOM Trial Results for Weight Management; NDA Submission on Track for December
11. Arena Pharmaceuticals to Host Conference Call and Webcast on Friday, September 18, 2009, to Discuss Results from the BLOSSOM Phase 3 Trial of Lorcaserin for Weight Management
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/20/2014)... , Aug. 20, 2014  Quantum Materials Corporation ... sets of patent families from Bayer Technology Services GmbH, ... for Bayer AG of Leverkusen, Germany ... provide broad intellectual property protection for advances ... quantum dot (QD) manufacturing. In addition, the Bayer ...
(Date:8/20/2014)... Glenmark Pharmaceuticals S.A. (GPSA), ... India (GPL), announces the discovery and initiation of ... candidate, GBR 1302, a HER2xCD3 bispecific antibody. GBR ... Biologics Research Centre located in La Chaux-de-Fonds, ... on Glenmark,s innovative BEAT antibody technology platform which ...
(Date:8/20/2014)... 20, 2014 Phase I Trial ... US  KalVista Pharmaceuticals ("KalVista"), an ophthalmology company ... announces that it has begun a Phase I, First ... KVD001, for the treatment of DME. The study,s Principal ... Eye Institute, Joslin Diabetes Center; Harvard Medical School Department ...
Breaking Medicine Technology:Quantum Materials Acquires Bayer Technology Services Quantum Dot Manufacturing and Quantum Dot Solar Cell Patents 2Quantum Materials Acquires Bayer Technology Services Quantum Dot Manufacturing and Quantum Dot Solar Cell Patents 3Quantum Materials Acquires Bayer Technology Services Quantum Dot Manufacturing and Quantum Dot Solar Cell Patents 4Glenmark Enters Oncology With the Discovery and Initiation of IND Enabling Studies of an Innovative Bispecific Antibody 2Glenmark Enters Oncology With the Discovery and Initiation of IND Enabling Studies of an Innovative Bispecific Antibody 3KalVista Pharmaceuticals Announces Start of Clinical Development for Novel Treatment for Diabetic Macular Edema 2KalVista Pharmaceuticals Announces Start of Clinical Development for Novel Treatment for Diabetic Macular Edema 3KalVista Pharmaceuticals Announces Start of Clinical Development for Novel Treatment for Diabetic Macular Edema 4
... Information Systems ("SIS"), a leader in perioperative ... leadership in achieving clinical, financial, and operational goals ... the company,s annual client conference, the 2012 SIS ... systems exemplifying the innovative use of information technology ...
... 2012 Top leaders representing America,s advanced medical ... public policy issues affecting job creation and medical innovation and ... billion medical device tax set to begin in January 2013. ... Renacci (R-Ohio) joined Walter M Rosebrough, president and CEO of ...
Cached Medicine Technology:Surgical Information Systems Recognizes Clients for Financial, Clinical, and Operational Improvements 2Surgical Information Systems Recognizes Clients for Financial, Clinical, and Operational Improvements 3Surgical Information Systems Recognizes Clients for Financial, Clinical, and Operational Improvements 4AdvaMed & BioOhio Discuss MedTech Impact on Ohio's Economy, Job Creation 2AdvaMed & BioOhio Discuss MedTech Impact on Ohio's Economy, Job Creation 3
(Date:8/20/2014)... CA (PRWEB) August 20, 2014 If old ... found a cure for it. With extensive research on HGH ... named ‘MetroMD’ claims to have perfected the art of rubbing ... a brand new younger look with their revolutionary anti-aging hormone ... of the 21st century fountain of youth, the MD of ...
(Date:8/20/2014)... (PRWEB) August 20, 2014 The ... a five-year, $1.24 million Science Education Partnership Award ... to support NAHN’s collaborative project with the Hispanic ... Health Careers. , This collaborative NIH R25 program ... cultural and linguistic diversity among health professionals by ...
(Date:8/20/2014)... Utah (PRWEB) August 20, 2014 Today, ... new information on open enrollment for 2015. , According ... insurance coming up in November, employees are encouraged to ... seeking coverage in 2015, the open enrollment period will ... During open enrollment 2015 individuals can purchase a new ...
(Date:8/20/2014)... 2014 Attendees of Seedstock’s 3rd Annual ... at Los Angeles’ first multi-faceted food production business incubator ... blossoming 1.5-acre high school campus urban farming operation in ... in the L.A. Art District. , The field trip, ... agriculture, will kick off Seedstock’s “Reintegrating Ag: Local Food ...
(Date:8/20/2014)... MA (PRWEB) August 20, 2014 Verndale ... annual Inc. 500|5000 list; an exclusive list ranking the ... list are ranked according to their yearly percentage revenue ... the 8th time on the Inc. 5000 list where ... Technology Company, Verndale offers its clients a wide range ...
Breaking Medicine News(10 mins):Health News:MetroMD Offers Revolutionary Anti-aging Hormone Therapy in Hollywood Area 2Health News:National Association of Hispanic Nurses (NAHN) Receives Five-Year Federal Grant from the National Institutes of Health (NIH) 2Health News:National Association of Hispanic Nurses (NAHN) Receives Five-Year Federal Grant from the National Institutes of Health (NIH) 3Health News:Seedstock Sustainable Agriculture Conference’s Urban Farm Field Trip to Offer First Look at Los Angeles’ Premier Food Business Incubator 2Health News:Seedstock Sustainable Agriculture Conference’s Urban Farm Field Trip to Offer First Look at Los Angeles’ Premier Food Business Incubator 3Health News:For the 8th Time, Verndale Has Been Honored on the Inc. 5000 List 2
... Inc. (Nasdaq: CADX ) announced today that it ... a private placement approximately 12 million shares of the Company,s ... million additional shares of the Company,s common stock, for aggregate ... paid for the common stock, $7.13 per share, is equal ...
... 4:00 PM ET - VALENCIA, Calif., Feb. 17 /PRNewswire-FirstCall/ ... ) today reported financial results for the fourth quarter ... of 2008, total operating expenses were $81.8 million, compared ... Research and development (R&D) expenses increased by $2.0 million ...
... bulk of cases, study finds, , , TUESDAY, Feb. 17 (HealthDay ... loss also have eye disorders, a new study has found. ... ear or to the nerves that link the ear to ... according to background information in the study. Half of all ...
... announced today that it has,received certification of its full ... Standards by the Jefferson School of,Population Health. , ... 10 Quality and Safety Standards in,March of 2007 with ... as its Clinical Advisory Board. A condition of CCA,membership ...
... HotHead Technologies, Inc. today,announced that the technology they ... Kennesaw State University researchers as an early,warning ... "It,s exciting news that research from a university as ... verify much earlier than we anticipated, in,the preliminary stages ...
... Light Press, LLC announces the audio edition of "That,s ... written by co-authors Lil Ingram and Marlene Lee, and ... of HOPE is available in MP3 format at no ... will also be available via the website for the ...
Cached Medicine News:Health News:Cadence Pharmaceuticals to Raise $86.6 Million in a Private Placement of Common Stock 2Health News:Cadence Pharmaceuticals to Raise $86.6 Million in a Private Placement of Common Stock 3Health News:MannKind Corporation Reports Fourth Quarter and Full Year 2008 Financial Results 2Health News:MannKind Corporation Reports Fourth Quarter and Full Year 2008 Financial Results 3Health News:MannKind Corporation Reports Fourth Quarter and Full Year 2008 Financial Results 4Health News:MannKind Corporation Reports Fourth Quarter and Full Year 2008 Financial Results 5Health News:MannKind Corporation Reports Fourth Quarter and Full Year 2008 Financial Results 6Health News:MannKind Corporation Reports Fourth Quarter and Full Year 2008 Financial Results 7Health News:Eye Problems, Hearing Loss May Be Linked 2Health News:RediClinic Meets Strict Quality and Safety Standards for Retail Clinics 2Health News:RediClinic Meets Strict Quality and Safety Standards for Retail Clinics 3Health News:RediClinic Meets Strict Quality and Safety Standards for Retail Clinics 4Health News:HotHead Technologies' Heat Sensor Shows Exciting Potential by Kennesaw State University Researchers 2Health News:'That's My Hope' Audio Edition Released 2Health News:'That's My Hope' Audio Edition Released 3
... your expectations with state of the art ... customized to meet the needs of your ... can be upgraded to grow with you. ... database management, it is easy to see ...
... ultimate flexibility by allowing you to determine ... display. Wall-mount anywhere in the room. Further ... laptop, touch screen tablet, industrial PC, desktop ... multi-function patient tower provides more power and ...
... capabilities combined with ease of use make ... its class. Ideal for office or hospital-based ... for Uroflowmetry, cystometry, leak point pressure, or ... available which make the OM-5 flexible enough ...
... combined with ease of use make the ... class. Ideal for office or hospital-based urodynamics, ... Uroflowmetry, cystometry, leak point pressure, or urethral ... which make the OM-5 flexible enough to ...
Medicine Products: